MX2009007597A - Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. - Google Patents

Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.

Info

Publication number
MX2009007597A
MX2009007597A MX2009007597A MX2009007597A MX2009007597A MX 2009007597 A MX2009007597 A MX 2009007597A MX 2009007597 A MX2009007597 A MX 2009007597A MX 2009007597 A MX2009007597 A MX 2009007597A MX 2009007597 A MX2009007597 A MX 2009007597A
Authority
MX
Mexico
Prior art keywords
therapy
medicament
ligands
treating cancer
integrin ligands
Prior art date
Application number
MX2009007597A
Other languages
English (en)
Inventor
Simon Goodman
Andreas Harstrick
Martin Andreas Picard
Johannes Nippgen
Ulrike Grimm
Roger Stupp
Michael Weller
Stefan Krueger
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/001446 external-priority patent/WO2007084670A2/en
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2009007597A publication Critical patent/MX2009007597A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a una terapia de combinación para el tratamiento de tumores y metástasis de tumores que comprende la administración de ligandos de integrina, preferiblemente antagonistas de integrina, junto con agentes co-terapéuticos o formas de terapia que tienen eficacia sinérgica cuando se administran consecutivamente con los ligandos, tales como agentes quimioterapéuticos y/o terapia de radiación. La terapia da por resultado un incremento potencial sinérgico del efecto inhibidor de cada agente terapéutico individual sobre la proliferación de células tumorales, para producir un tratamiento más efectivo que aquel que se encuentra al administrar un componente individual solo, concurrentemente o no en el régimen de dosificación de la presente invención.
MX2009007597A 2007-01-18 2008-01-17 Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. MX2009007597A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2007/001446 WO2007084670A2 (en) 2006-01-18 2007-01-18 Specific therapy using integrin ligands for treating cancer
EP07014070 2007-07-18
PCT/EP2008/000328 WO2008087025A2 (en) 2007-01-18 2008-01-17 Specific therapy and medicament using integrin ligands for treating cancer

Publications (1)

Publication Number Publication Date
MX2009007597A true MX2009007597A (es) 2009-07-22

Family

ID=39402737

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007597A MX2009007597A (es) 2007-01-18 2008-01-17 Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.

Country Status (19)

Country Link
US (2) US20100069302A1 (es)
EP (4) EP2101805B1 (es)
JP (3) JP2010516645A (es)
KR (2) KR20090108713A (es)
CN (2) CN101588812A (es)
AU (2) AU2008207095B2 (es)
BR (2) BRPI0806596A2 (es)
CA (2) CA2675813A1 (es)
CO (1) CO6382135A2 (es)
DK (1) DK2101805T3 (es)
EA (2) EA017864B1 (es)
EC (1) ECSP109969A (es)
ES (2) ES2399159T3 (es)
IL (1) IL199696A0 (es)
MX (1) MX2009007597A (es)
PL (1) PL2101805T3 (es)
PT (1) PT2101805E (es)
WO (2) WO2008087025A2 (es)
ZA (1) ZA200905703B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090108713A (ko) * 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
WO2010057596A2 (en) * 2008-11-20 2010-05-27 Merck Patent Gmbh New therapy and medicament using integrin ligands for treating cancer
SG176103A1 (en) * 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
CA2775601C (en) 2009-09-28 2017-10-03 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
WO2011146819A2 (en) * 2010-05-20 2011-11-24 Dmd Therapies, Llc METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES
US20150309012A1 (en) * 2012-12-07 2015-10-29 Baxter International Inc. Anti-mif antibody cell migration assay
US20160317531A1 (en) * 2013-06-21 2016-11-03 The General Hospital Corporation Ribonucleotide reductase inhibitors sensitize tumor cells to dna damaging agents
KR101579054B1 (ko) * 2014-03-26 2015-12-21 한국원자력의학원 포도필로톡신 아세테이트를 유효 성분으로 포함하는 방사선치료 증진제
ES2897782T3 (es) * 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
CA2966288A1 (en) 2014-10-30 2016-05-06 Big Dna Ltd Combination therapy
EP3207937A1 (en) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland A method of treating or preventing sepsis
CN105906692A (zh) * 2016-03-11 2016-08-31 李书鹏 cRGD-厄洛替尼缀合物及其制备方法
GB2554333A (en) * 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
WO2018145076A1 (en) * 2017-02-06 2018-08-09 Expression Pathology, Inc. Quantifying mgmt protein for optimal cancer therapy
JP2024512824A (ja) 2021-01-22 2024-03-19 ロイヤル カレッジ オブ サージャンズ イン アイルランド コロナウイルスの治療

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701446A (en) 1901-12-30 1902-06-03 Lewis W Wooten Cotton-chopper.
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
EP0553244B8 (en) 1990-10-05 2005-06-08 Celldex Therapeutics, Inc. Targeted immunostimulation with bispecific reagents
CA2097060A1 (en) 1990-12-04 1992-06-05 Peter J. Curtis Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
DE69528829T2 (de) 1994-05-27 2003-08-07 Merck & Co., Inc. Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
EP0762882A4 (en) 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
EP0767792A4 (en) 1994-06-29 2002-11-20 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
IT1271688B (it) 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
DE69519300T2 (de) * 1994-08-08 2001-05-31 Debiopharm S.A., Lausanne Stabiles arzneimittel enthaltend oxaliplatin
EP0777657A1 (en) 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
WO1997001540A1 (en) 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
WO1997045447A1 (en) 1996-05-31 1997-12-04 The Scripps Research Institute METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
IL125034A0 (en) 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
CN1209063A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
CZ203698A3 (cs) 1995-12-29 1999-05-12 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
BR9708231A (pt) 1996-03-20 1999-08-03 Hoechst Marion Roussel Inc Compostos tricíclicos que têm uma atividade face a integrinas principalmente face à integrina alfavbeta3 seu processo de preparação e os intermediários desse processo sua aplicação a título de medicamentos e composiçóes farmacêuticas que os contêm
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
ES2185009T3 (es) 1996-04-10 2003-04-16 Merck & Co Inc Antagonistas de alfa y beta 3'.
WO1997041844A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
EP0934305A4 (en) 1996-08-29 2001-04-11 Merck & Co Inc INTEGRINE ANTAGONISTS
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
ES2194223T3 (es) 1996-10-30 2003-11-16 Merck & Co Inc Antagonistas de la integrina.
JP2001504456A (ja) 1996-10-30 2001-04-03 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
EP0963370B1 (en) 1996-12-09 2003-03-19 Eli Lilly And Company Integrin antagonists
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
AU729869B2 (en) 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
JP2002510328A (ja) 1997-07-25 2002-04-02 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
EP1007051A4 (en) 1997-08-04 2001-08-29 Smithkline Beecham Corp INTEGRIN RECEPTOR ANTAGONISTS
WO1999011626A1 (en) 1997-09-04 1999-03-11 Smithkline Beecham Corporation Integrin receptor antagonists
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
AU9577498A (en) 1997-09-24 1999-04-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
IL135188A0 (en) 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
FR2768734B1 (fr) 1997-09-24 2000-01-28 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
EP1040111B1 (en) 1997-12-17 2005-06-22 Merck & Co., Inc. Integrin receptor antagonists
AU738452B2 (en) 1997-12-17 2001-09-20 Merck & Co., Inc. Integrin receptor antagonists
HUP0100397A3 (en) 1997-12-17 2002-10-28 Merck & Co Inc Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP1049718B1 (en) 1998-01-23 2006-04-05 MERCK PATENT GmbH Use of the antibody 271.14d9.f8 (dsm acc2331) to inhibit in vitro alphavbeta6-integrin attachment to fibronectin
EP1100506A4 (en) 1998-07-29 2002-06-26 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038718A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
DZ3263A1 (fr) 1999-06-02 2000-12-07 Merck & Co Inc Antagonistes du recepteur de l'alpha v integrine
WO2001090384A1 (en) * 2000-05-19 2001-11-29 The Board Of Trustees Of The Leland Stanford Junior University Viral vectors useful in induction of humoral or cellular immunity
CA2422890C (en) 2000-09-29 2013-04-23 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
RU2292904C2 (ru) * 2001-01-09 2007-02-10 Мерк Патент Гмбх Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса
EP1381384B1 (en) * 2001-04-24 2011-05-25 Merck Patent GmbH COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
WO2007084670A2 (en) * 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
KR20090108713A (ko) * 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약

Also Published As

Publication number Publication date
BRPI0813513A2 (pt) 2015-01-06
EP2101805B1 (en) 2012-11-07
CN101743013A (zh) 2010-06-16
WO2009010287A3 (en) 2009-04-09
AU2008277904A1 (en) 2009-01-22
CO6382135A2 (es) 2012-02-15
KR20100043242A (ko) 2010-04-28
AU2008207095A1 (en) 2008-07-24
BRPI0806596A2 (pt) 2013-07-23
EP2164506A2 (en) 2010-03-24
AU2008207095B2 (en) 2013-08-29
CA2693862A1 (en) 2009-01-22
ZA200905703B (en) 2010-05-26
ECSP109969A (es) 2010-03-31
EA017864B1 (ru) 2013-03-29
EP2101805A2 (en) 2009-09-23
ES2472450T3 (es) 2014-07-01
KR20090108713A (ko) 2009-10-16
JP2010533665A (ja) 2010-10-28
EA200900912A1 (ru) 2009-12-30
CN101588812A (zh) 2009-11-25
EP2441464A1 (en) 2012-04-18
WO2008087025A3 (en) 2008-12-11
JP2014015482A (ja) 2014-01-30
WO2008087025A2 (en) 2008-07-24
US20100190957A1 (en) 2010-07-29
IL199696A0 (en) 2010-04-15
EP2441464B1 (en) 2014-04-09
EA201000127A1 (ru) 2010-10-29
DK2101805T3 (da) 2013-01-21
ES2399159T3 (es) 2013-03-26
WO2009010287A2 (en) 2009-01-22
PL2101805T3 (pl) 2013-04-30
CA2675813A1 (en) 2008-07-24
PT2101805E (pt) 2013-01-31
US20100069302A1 (en) 2010-03-18
JP2010516645A (ja) 2010-05-20
EP2578225A1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
WO2007084670A3 (en) Specific therapy using integrin ligands for treating cancer
MX2009007597A (es) Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
MX2011012491A (es) Administracion continua de cilengitida en tratamientos contra el cancer.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
SG10201902664RA (en) Combination therapy for treating cancer
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2011013424A (es) Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2015015434A (es) Corroles dirigidas para toxicidad tumoral y rm.
WO2015035410A8 (en) Cancer therapy
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
AR049135A1 (es) Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib
WO2010057596A3 (en) New therapy and medicament using integrin ligands for treating cancer
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
WO2007082742A8 (en) Isolated organ perfusion combination therapy of cancer
MX2015007280A (es) Terapia de combinacion para cancer.
MX2020006808A (es) Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral.
WO2014115859A3 (ja) 分子標的併用腫瘍治療・予防薬
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration